Accent Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Accent Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-193	Closed	-$6.82K	–	359
2026 Q1	$6.82K	Hold	193	–	–	﹤0.01%	243
2025 Q4	$5.4K	Hold	193	–	–	﹤0.01%	290
2025 Q3	$5.79K	Hold	193	–	–	﹤0.01%	296
2025 Q2	$5.52K	Buy	+193	New	+$5.52K	﹤0.01%	321

Accent Capital Management's ALXN Position: Q2 2026 in Review

Accent Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2026, closing a stake of 193 shares — an estimated $6.82K sold.

Accent Capital Management first reported a position in ALXN in Q2 2025 and held it in 4 quarters. The position peaked at $6.82K in Q1 2026. 0 funds tracked by Wall St. Rank hold ALXN as of Q2 2026.

Accent Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Accent Capital Management sold 193 Alexion Pharmaceuticals shares in Q2 2026, an estimated $6.82K.
Accent Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Accent Capital Management's Alexion Pharmaceuticals position peaked at $6.82K in Q1 2026.
0 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2026.

Based on Accent Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.